VANCOUVER, BRITISH COLUMBIA--(Marketwire - August 26, 2008) - Tekmira Pharmaceuticals Corporation (TSX: TKM) announced today that it has published new research that highlights proprietary technology developed by the company to modify small interfering RNA (siRNA) molecules to minimize the immune stimulation effects of siRNA while preserving their RNA interference (RNAi) activity. Tekmira's siRNA modification technology, which the company has filed intellectual property to protect, will be utilized in its product candidates.
